Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
NCT02203526
Recruiting
BACKGROUND: * Primary CNS lymphoma (PCNSL) is a rare subtype of diffuse large B-cell lymphoma. * The outcome for patients with this diagnosis is significantly worse than for that of systemic DLBCL. Most treatment approaches in the past have included high dose methotrexate and radiation treatment. * Most PCNSLs appear to be of activated B-cell (ABC) origin. * Ibrutinib is an inhibitor of Bruton s tyrosine kinase (BTK) and effective for systemic DLBCL of ABC origin. * We propose doing a study in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Primary Central Nervous System Lymphoma
Register for Updates
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT03959085
Recruiting
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin.... Read More
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
03/18/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +228 locations
Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Register for Updates
Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
NCT04781322
Recruiting
Background: Drinking alcohol can lead to swelling and injury in the liver. Long-term heavy drinking may lead to liver disease. Researchers want to study the relationship between a drug called alirocumab, alcohol use, and liver functioning/swelling. Objective: To study the effects of alirocumab in people who drink alcohol. Eligibility: Healthy adults ages 21 to 65 who regularly consume an average of 20 or more drinks per week. Design: Participants will be screened under protocol 14-AA-0181... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
03/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Alcohol Associated Liver Disease, Heavy Drinking Behavior
Register for Updates
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
NCT05304585
Recruiting
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma. Another aim of the study it to find out how well patients with low risk rhabdomyosarcoma (LR-... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/18/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +166 locations
Conditions: Embryonal Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
Register for Updates
δ in Dementia Clinical Trials
NCT05592678
Recruiting
The goal of this clinical trial is to demonstrate potential improvements in clinical trial methods relating to dementia and cognitive decline. The main questions it aims to answer are: * Can an intervention's outcome be better assessed by a latent variable ("δ") integrating cognitive performance with functional status? * Can latent biomarkers of δ guide the selection of an intervention that will modulate dementia severity? * Can a latent variable, derived from information collected remotely fro... Read More
Gender:
ALL
Ages:
Between 65 years and 100 years
Trial Updated:
03/18/2025
Locations: Univeristy of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas
Conditions: Alzheimer's Disease (AD), Dementia, Cognitive Decline, Mild Cognitivie Impairment (MCI)
Register for Updates
BE WELL With Migraine: Brain Education and WELLness With Migraine
NCT05987592
Recruiting
The goal of this randomized clinical trial is to evaluate two different non-drug, virtual treatment options designed to improve the lives of patients with migraine. Both interventions involve 8 weekly sessions and an online platform with additional content and learning. Participants can stay on all their medications during this study. Information from this study may help determine how to better treat migraine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Cambridge Health Alliance - Center for Mindfulness and Compassion, Cambridge, Massachusetts +2 locations
Conditions: Migraine
Register for Updates
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
NCT06347705
Recruiting
The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells. Researchers will look at whether this treatment approach is able to completely get rid of cancer in participants, and they will check for the presence of minimal residual disease (MRD) in participants. MRD is a small number of cancer cells that can be detected in the bo... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Prostate Cancer
Register for Updates
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
NCT06717243
Recruiting
The goal of this observational study is to understand how genomic and epigenetic factors contribute to resistance against chemo-immunotherapy in adults diagnosed with extensive-stage small cell lung cancer (ES-SCLC) or metastatic large cell neuroendocrine carcinoma (LCNEC). Both ES-SCLC and LCNEC are aggressive forms of lung cancer with limited treatment options and poor prognosis. While initial responses to chemo-immunotherapy are often promising, most patients develop resistance within a few m... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/18/2025
Locations: Icahn School of Medicine at Mount Sinai, New York, New York +1 locations
Conditions: Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure, Biomarkers / Blood, Biomarkers, Immunotherapy
Register for Updates
Novel Genetic Disorders of the Immune System
NCT02257892
Recruiting
Background: - The immune system helps the body fight infection and disease. People with immune system problems can get infections, blood disorders, and other health problems. Researchers want to learn more about the immune system, like what causes it to not work properly. Objectives: - To evaluate people with certain types of immune system disorders. Eligibility: - Adults and children with an immune disorder or symptoms of one, and their relatives. Some disorders are not included in this st... Read More
Gender:
ALL
Ages:
Between 3 years and 99 years
Trial Updated:
03/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: PI3KCD, CTLA4, STAT3GOF, MAGT1
Register for Updates
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
NCT04097145
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: Banner University Medical Center Phoenix, Phoenix, Arizona +78 locations
Conditions: Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
Register for Updates
Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer
NCT04847466
Recruiting
Background: Immunotherapy is a powerful tool in the fight against cancer. It uses the body s own immune system to fight the cancer. Unfortunately, cancer cells can find ways to escape from destruction by the body s immune system, even when immunotherapy is used. Natural killer (NK) cells are an important part of the body s immune system and can help fight cancer. In combination with immunotherapy, researchers are using engineered NK cells that recognize and kill cancer cells trying to escape d... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC
Register for Updates
Phase 2/3 Adaptive Study of VX-147 in Adults With APOL1-mediated Proteinuric Kidney Disease
NCT05312879
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of VX-147 in participants aged 18 years and older with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/18/2025
Locations: Alabama Kidney Research, Alabaster, Alabama +303 locations
Conditions: Proteinuric Kidney Disease
Register for Updates